Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer

2017 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer​
Hagemann, J.; Jacobi, C.; Hahn, M.; Schmid, V.; Welz, C.; Schwenk-Zieger, S. & Stauber, R. et al.​ (2017) 
Anticancer Research37(5) pp. 2201​-2210​.​ DOI: https://doi.org/10.21873/anticanres.11555 

Documents & Media

document.pdf435.36 kBAdobe PDF

License

GRO License GRO License

Details

Authors
Hagemann, Jan; Jacobi, Christian; Hahn, Moritz; Schmid, Vanessa; Welz, Christian; Schwenk-Zieger, Sabina; Stauber, Roland; Baumeister, Philipp; Becker, Sven
Abstract
Background/Aim: Chemo-radiation currently serves as first-line therapy of advanced and recurrent head and neck cancer, while new chemotherapy regimens are emerging. However, response rates to any treatment are difficult to predict and underlie broad variation. This study shows the development of a standardized, high-throughput in vitro assay to assess patients' individual response to therapy regimens as a future tool for personalized tumor therapy. Materials and Methods: Viability and proliferation analyses after chemo +/- radiation treatment of single spheroids (low adhesion plates/Hanging Drop (HD)) were generated from head and neck squamous cell carcinoma (HNSCC) cell lines and primary human cells from fresh tumor specimens. Results: All cell lines showed reliable growth in all cell culture methods. The spheroids showed significant delay of growth and/or necrosis compared to control groups when exposed to current standard chemotherapeutic regimens. Single 3D spheroids ready for therapy susceptibility testing could be generated from actual tumor specimens after enzymatic and mechanical separation. Conclusion: In its current form, this single spheroid-based in vitro assay was able to test individual therapy susceptibility to current standard therapy regimens or, potentially, for testing new targeted drugs in HNSCC treatment. With recent discoveries regarding tumor heterogeneity and individual mutation status, a reliable assay is a prerequisite for personalized therapy in head and neck cancer.
Issue Date
2017
Status
published
Publisher
Int Inst Anticancer Research
Journal
Anticancer Research 
ISSN
1791-7530; 0250-7005
Sponsor
Universitat Munchen

Reference

Citations


Social Media